Latest market price
233.35
+6.23+2.74%
OverviewShort InterestFilings
STEQT52STERIS plc·NYSE
233.35+2.74%
Earnings
Up 2.7% — Earnings due 2026-11-04 — pre-report positioning.
Medium confidence
TA
Loading chart...
Signal & projected range
Analyst consensus risingHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
ALC+3.05%$73.63QDEL+5.89%$14.03MLAB-4.57%$121.97BWAY-2.38%$11.09MASS-9.24%$10.21SI+0.99%$19.32MOBI-4.82%$10.07LAB-0.02%$0.61
Snapshot
IndexS&P 500P/E28.53EPS (ttm)8.18Insider Own0.45%Shs Outstand97.50MPerf Week1.40%
Market Cap22.75BForward P/E19.03EPS next Y12.26Insider Trans-2.58%Shs Float97.17MPerf Month11.90%
Enterprise Value24.28BPEG3.04EPS next Q2.67Short Float2.47%Perf Quarter0.21%
Income805.00MP/S3.77EPS this Y9.97%Short Ratio3.53Perf Half Y9.94%
Sales6.04BP/B3.15EPS next Y9.35%ROA7.50%Short Interest2.40MPerf YTD-7.96%
Book/sh74.06P/C47.20EPS next 5Y9.40%ROE11.27%52W High269.44 -13.39%Perf Year-1.20%
Cash/sh4.94P/FCF24.57EPS past 3/5Y94.97% 11.36%ROIC8.71%52W Low195.14 19.58%Perf 3Y11.44%
Dividend Est.2.76 (1.18%)EV/EBITDA14.89Sales past 3/5Y9.38% 13.82%Gross Margin44.43%Volatility2.22% 2.34%Perf 5Y-0.86%
Dividend TTM2.58 (1.11%)EV/Sales4.02EPS Y/Y TTM25.27%Oper. Margin18.91%ATR (14)5.28Perf 10Y241.30%
Dividend Ex-DateNov 17, 2026Quick Ratio1.35Sales Y/Y TTM8.35%Profit Margin13.34%RSI (14)63.49Recom2.14
Dividend Gr. 3/5Y10.06% 9.28%Current Ratio1.91EPS Q/Q10.68%SMA204.70%Beta0.85Target Price271.33
Payout30.68%Debt/Eq0.28Sales Q/Q7.33%SMA506.19%Rel Volume0.91Prev Close227.12
Employees17,937LT Debt/Eq0.24EarningsNov 04SMA2003.92%Avg Volume678.78KPrice233.35
IPO DateJun 01, 1992Option/ShortYes / YesEPS/Sales Surpr.3.82% 0.34%Net Debt/EBITDA0.94Volume616,885Change2.74%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-28-26InitiatedUBSBuy$275
May-21-26ReiteratedPiper SandlerOverweight$260 → $270
May-13-26ReiteratedKeybancOverweight$265 → $269
Jul-15-25UpgradeMorgan StanleyEqual Weight → Overweight
Oct-24-24UpgradePiper SandlerNeutral → Overweight$225 → $260
Sep-03-24ReiteratedKeyBancOverweight$255 → $265
May-10-24ReiteratedPiper SandlerNeutral$225
Apr-04-24ReiteratedWolfe Research$245
Apr-14-23DowngradePiper SandlerOverweight → Neutral
Sep-23-22DowngradeNeedhamBuy → Hold
Latest News· Times ET
Oct-31-26
Oct-31-2603:08AM
STERIS (STE) Dividend Reaffirms The Story As Undervalued Views Face A P E RealityYahoo
Oct-30-26
Oct-30-2611:51AM
STERIS Set to Report Q2 Earnings: What's in the Cards for the Stock?zacks.com
Oct-29-26
Oct-29-2609:46AM
2 Healthcare Technology Stocks for a Digital Health Boomzacks.com
Oct-28-26
Oct-28-2604:30PM
STERIS Announces Dividend of $0.69 per shareglobenewswire.com
Oct-23-26
Oct-23-2612:24PM
Is Ecolab Still The Business You Bought?Yahoo
Oct-22-26
Oct-22-2608:00PM
Steris PLC (STE) Shares Surge 4.8% -- What GF Score of 90 Tells Investorsgurufocus.com
Oct-20-26
Oct-20-2604:30PM
STERIS to Host a Conference Call for Fiscal 2027 Second Quarter on November 5, 2026globenewswire.com
Oct-16-26
Oct-16-2609:15AM
Reasons to Add STE Stock to Your Portfolio Right Nowzacks.com
Oct-13-26
Oct-13-2610:00AM
Steris inks $2.1B Xodus buyout to expand consumables portfolioYahoo
07:25AM
STERIS plc $STE Shares Bought by Perpetual Ltddefenseworld.net
Oct-12-26
Oct-12-2602:43PM
Xodus Medical Announces Agreement to Be Acquired by STERIS (NYSE: STE)prnewswire.com
09:11AM
Steris to Acquire Xodus Medical for $2.1 Billionwsj.com
Sep-29-26
Sep-29-2605:34AM
Rep. Kevin Hern Unloads Shares of Honeywell International Inc. (NASDAQ:HON)defenseworld.net
05:03AM
Crane (NYSE:CR) Stock Sold Off by Rep. Kevin Herndefenseworld.net
05:03AM
Colgate-Palmolive (NYSE:CL) Stock Sale Revealed by Rep. Kevin Herndefenseworld.net
Company

STERIS plc provides infection prevention products and services in the United States, Ireland, and internationally. The company operates through three segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. It offers a range of products including cleaning chemistries, sterility assurance products, automated endoscope reprocessing systems, surgical tables, lights, and connectivity solutions. It also provides services such as equipment maintenance, instrument repair, and contract sterilization for medical device and pharmaceutical manufacturers.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2026
3/31/2026
FY 2025
3/31/2025
FY 2024
3/31/2024
FY 2023
3/31/2023
FY 2022
3/31/2022
FY 2021
3/31/2021
FY 2020
3/31/2020
FY 2019
3/31/2019
Total Revenue6,0375,9365,4605,139—————
Cost of Goods Sold Incl. D&A3,3553,3093,0572,921—————
Gross Profit2,6832,6272,4032,218—————
Selling, General and Administrative Excl. Other1,0541,4081,3341,252—————
Research and Development116113108104—————
Other Operating Expense37149426—————
Operating Income1,1421,102867836—————
Interest Expense616186144—————
Unusual Expense
—————————
Non-Operating Income (Expense)961611—————
Net Income Before Taxes1,0901,047796703—————
Income Taxes282262185150—————
Consolidated Net Income805785615378—————
Net Income From Continuing Operations808785612553—————
Net Income805785615378—————
EPS (Recurring)8.207.936.243.83—————
EPS (Basic, Before Extraordinaries)8.207.936.243.83—————
EPS (Diluted)8.187.936.203.81—————
EBITDA1,6301,5951,3591,412—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio28.5327.8936.5659.01—————
Price To Sales Ratio3.793.654.114.33—————
Gross Margin44.4444.2644.0143.16—————
Operating Margin18.9218.5615.8816.27—————
Net Margin13.3313.2211.267.36—————
Shares Outstanding98989999—————
Market Capitalization22,86821,67122,43822,257—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$279.04$256.53$234.02$211.52$189.01● Close Price0.00M1.46M2.92M4.38M5.83MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Sohi MohsenDirectorAug 12 '26Option Exercise86.234,058349,92128,363Aug 12
Sohi MohsenDirectorAug 12 '26Sale235.784,058956,79524,305Aug 12
Sohi MohsenDirectorJul 01 '26Option Exercise71.403,781269,96326,142Jul 02
Zangerle John AdamSr. VP, Gen Counsel, and Sec.Jun 15 '26Sale209.281,419296,96835,259Jun 16
Carestio Daniel APresident and CEOJun 05 '26Sale212.001,374291,28863,647Jun 08
Carestio Daniel APresident and CEOJun 04 '26Sale214.643,054655,51165,021Jun 08
Burton Karen LSr. Vice Pres., CFOJun 02 '26Option Exercise209.766613,84413,464Jun 04
Breeden Richard CDirectorJun 02 '26Option Exercise71.403,781269,96340,445Jun 04
Breeden Richard CDirectorJun 02 '26Sale209.511,481310,28438,964Jun 04
FELDMANN CYNTHIA LDirectorMar 05 '26Option Exercise152.323,098471,8873,803Mar 06
FELDMANN CYNTHIA LDirectorMar 05 '26Sale237.213,098734,877705Mar 06
Madsen JuliaSr. VP and GM, Life SciencesNov 21 '25Option Exercise128.225,008642,13913,582Nov 25
Madsen JuliaSr. VP and GM, Life SciencesNov 21 '25Sale262.002,136559,63210,710Nov 25
Tamaro RenatoV.P. & Corporate TreasurerNov 18 '25Option Exercise182.223,536644,33010,731Nov 20
Tamaro RenatoV.P. & Corporate TreasurerNov 18 '25Sale257.555,0361,297,0395,695Nov 20
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.